[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-165445-en":3,"doc-seo-165445-105":30,"detail-sidebar-cat-1-en-105":91},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":11,"category_id":12,"category_name":13,"doc_title":14,"doc_description":15,"doc_content":16,"file_id":17,"file_url":18,"file_type":19,"file_size":20,"view_count":4,"is_deleted":4,"is_public":11,"is_downloadable":11,"audit_status":11,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":27,"seo_description":15,"update_tm":28,"read_time":29},165445,962085564807,"Rizky","https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8",1,17,"Forms","HIV Post Exposure Prophylaxis（PEP）Patient Group Direction（PGD）模板 - Version 2.0","Patient Group Direction（PGD）模板用于在指定地点/服务/机构中供应依曲他滨/替诺福韦二丙酯与雷替拉韦片剂，以实施HIV暴露后预防（HIV PEP）。文件明确版本号2.0及变更记录，要求采用机构按其PGD治理体系完成正式签署与法定授权。模板包含人员特征、适用临床情境范围、供药/给药流程性说明，以及关键参考文献与附录，用于补充授权表单等本地合规信息。","[Insert the logo of the authorising body here\n[[\u0013 HYPERLINK \"https://www.nice.org.uk/guidance/mpg2/chapter/Recommendations\" \\l \"terms-used-in-the-guideline\" \u0014See the NICE guidance for the definition of an authorising body\u0015]]\nPatient Group Direction\nSupply of emtricitabine/tenofovir disoproxil and raltegravir tablets for HIV Post Exposure Prophylaxis (HIV PEP) in [location/service/organisation]\nVersion Number 2.0\nChange history\n[[Each organisation using this PGD must ensure that it is formally signed by a senior pharmacist, a senior doctor and any other professional group representatives involved in its review and that it is reviewed in line with the organisations’ PGD governance system.  The organisation’s governance lead must sign to authorise the PGD on behalf of the authorising organisation to ensure that this document meets legal requirements for a PGD.]]\n\u000fPGD development group\nThis PGD template has been peer reviewed by the PEP PGDs Short Life Working Group in accordance with their Terms of Reference. It has been approved by the British HIV Association (BHIVA), British Association for Sexual Health and HIV (BASHH) in Feb 2024.\nNote the working group and approving organisation(s) agreement to the content only applies to the national template and does not extend to any local adaptations made to any of the content which are solely the responsibility of the organisation authorising the PGD. The most up to date version of the template is available from the \u0013 HYPERLINK \"https://www.sps.nhs.uk/home/guidance/patient-group-directions-and-legal-mechanisms/national-pgd-protocol-and-written-instructions-templates/\" \u0014SPS national PGD, protocol and written instruction template webpage\u0015.\nThis section MUST REMAIN when a PGD is adopted by an organisation.\nThe PGD has also been reviewed by members of the Sexual Health PGDs Short Life Working Group in accordance with their Terms of Reference. It has been approved by the British HIV Association (BHIVA) and the British Association for Sexual Health and HIV (BASHH) in February 2024.\nGlossary\n\u000f\n[[The PGD template is not legally valid until it has had the relevant organisational approval.  See below.]]\nOrganisational authorisations [[and other legal requirements]]\n[[This page may be deleted if replaced with a format agreed according to local PGD policy with relevant approvals and authorisation.\nThe PGD is not legally valid until it has had the relevant organisational authorisations.\nTo ensure compliance with the law, organisations must add local authorisation details i.e. clinical authorisations and the person signing on behalf of the authorising organisation. You may either complete details below or delete and use a format agreed according to local PGD policy which complies with PGD legislation and \u0013 HYPERLINK \"https://www.nice.org.uk/Guidance/MPG2\" \u0014NICE MPG2 PGD 2017\u0015.]]\n[[It is the responsibility of the provider organisation to ensure that all legal and governance requirements for using the PGD are met.\nTo meet legal requirements, authorising organisations must add an Individual Practitioner Authorisation sheet or List of Authorised Practitioners. This varies according to local policy and how the service is managed but this should be a signature list or an individual agreement.\nPGDs do not remove inherent professional obligations or accountability. It is the responsibility of each professional to practice only within the bounds of their own competence and in accordance with their own Code of Professional Conduct.  Individual practitioners must declare that they have read and understood the Patient Group Direction and agree to supply/administer medicine listed only in accordance with the PGD.\nOrganisations may also add:\nLocal training and competency assessment documentation\nOther supporting local guidance or information\nLinks to local PGD Policy and other supporting guidance\nAudit requirements\nAny reference to a Trust protocol (either clinical to be followed as part of the supply of a medicin","cbCaihuljxffbBtb","https://ap.wps.com/l/cbCaihuljxffbBtb","docx",79135,20,"English","en",105,"# Patient Group Direction\n## Version Number and Change History\n## Glossary\n## Organisational authorisations and other legal requirements\n## Characteristics of staff\n## Clinical condition or situation to which this PGD applies\n## Description of treatment\n## Key references (last accessed January 2024)\n## Appendices\n## Appendix A - Registered health professional authorisation sheet","[{\"question\":\"该PGD模板的版本号是多少？\",\"answer\":\"文件中注明PGD模板的版本号为2.0。\"},{\"question\":\"PGD在法律上何时才有效？\",\"answer\":\"在完成相关机构的法定授权后，PGD才具有法律效力；未获得必要授权则不能依法使用。\"},{\"question\":\"使用该PGD模板需要哪些机构签署与治理要求？\",\"answer\":\"各使用机构需确保由高级药师、高级医生以及参与审阅的其他专业代表正式签署，并根据机构的PGD治理体系进行复核；治理负责人需代表授权机构签署以满足法律要求。\"}]","HIV Post Exposure Prophylaxis（PEP）Patient Group Direction（PGD）模板 - Version 2.0 | DOCX",1788171712,7,{"code":4,"msg":31,"data":32},"ok",{"site_id":24,"language":23,"slug":33,"title":14,"keywords":34,"description":15,"schema_data":35,"social_meta":86,"head_meta":88,"extra_data":90,"updated_unix":28},"hiv-post-exposure-prophylaxis-pep-patient-group-direction-pgd-template-version-20","",{"@graph":36,"@context":85},[37,54,68],{"@type":38,"itemListElement":39},"BreadcrumbList",[40,44,48,51],{"item":41,"name":42,"@type":43,"position":11},"https://docshare.wps.com","Home","ListItem",{"item":45,"name":46,"@type":43,"position":47},"https://docshare.wps.com/template/","Template",2,{"item":49,"name":13,"@type":43,"position":50},"https://docshare.wps.com/template/forms/",3,{"item":52,"name":14,"@type":43,"position":53},"https://docshare.wps.com/template/hiv-post-exposure-prophylaxis-pep-patient-group-direction-pgd-template-version-20/165445/",4,{"url":52,"name":14,"@type":55,"author":56,"headline":14,"publisher":58,"fileFormat":61,"inLanguage":23,"description":15,"dateModified":62,"datePublished":62,"encodingFormat":61,"isAccessibleForFree":63,"interactionStatistic":64},"DigitalDocument",{"name":9,"@type":57},"Person",{"url":41,"name":59,"@type":60},"DocShare","Organization","application/vnd.openxmlformats-officedocument.wordprocessingml.document","2026-08-31",true,{"@type":65,"interactionType":66,"userInteractionCount":4},"InteractionCounter",{"@type":67},"ViewAction",{"@type":69,"mainEntity":70},"FAQPage",[71,77,81],{"name":72,"@type":73,"acceptedAnswer":74},"该PGD模板的版本号是多少？","Question",{"text":75,"@type":76},"文件中注明PGD模板的版本号为2.0。","Answer",{"name":78,"@type":73,"acceptedAnswer":79},"PGD在法律上何时才有效？",{"text":80,"@type":76},"在完成相关机构的法定授权后，PGD才具有法律效力；未获得必要授权则不能依法使用。",{"name":82,"@type":73,"acceptedAnswer":83},"使用该PGD模板需要哪些机构签署与治理要求？",{"text":84,"@type":76},"各使用机构需确保由高级药师、高级医生以及参与审阅的其他专业代表正式签署，并根据机构的PGD治理体系进行复核；治理负责人需代表授权机构签署以满足法律要求。","https://schema.org",{"og:url":52,"og:type":87,"og:title":14,"og:site_name":59,"og:description":15},"article",{"robots":89,"canonical":52},"index,follow",{"doc_id":7,"site_id":24},{"code":4,"msg":5,"data":92},[93,98,103,108,113,118,121,126,131],{"id":94,"doc_module":11,"doc_module_name":46,"category_name":95,"show_sort_weight":96,"slug":97},11,"Presentations",90,"presentations",{"id":99,"doc_module":11,"doc_module_name":46,"category_name":100,"show_sort_weight":101,"slug":102},12,"Resumes",80,"resumes",{"id":104,"doc_module":11,"doc_module_name":46,"category_name":105,"show_sort_weight":106,"slug":107},14,"Invoices",70,"invoices",{"id":109,"doc_module":11,"doc_module_name":46,"category_name":110,"show_sort_weight":111,"slug":112},15,"Posters",60,"posters",{"id":114,"doc_module":11,"doc_module_name":46,"category_name":115,"show_sort_weight":116,"slug":117},16,"Social Media",50,"social-media",{"id":12,"doc_module":11,"doc_module_name":46,"category_name":13,"show_sort_weight":119,"slug":120},40,"forms",{"id":122,"doc_module":11,"doc_module_name":46,"category_name":123,"show_sort_weight":124,"slug":125},18,"Letters",30,"letters",{"id":127,"doc_module":11,"doc_module_name":46,"category_name":128,"show_sort_weight":129,"slug":130},21,"Paper Templates",5,"papers-templates",{"id":132,"doc_module":11,"doc_module_name":46,"category_name":133,"show_sort_weight":4,"slug":134},158,"General","general-158"]